APTOF and APS Related Headlines
Go Back- Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
- Aptose Reports First Quarter 2026 Results
- Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
- Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
- Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
- Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
- Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
- Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
- Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
- Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
- Aptose Reports Third Quarter 2025 Results
- Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
- Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
- Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
- Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
- Aptose reports positive early data for AML drug combination
- Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
- Aptose Reports Second Quarter 2025 Results
- Aptose advances tuspetinib to 160 mg dose in AML trial
- Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
- Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
- Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML
- Aptose Upgraded to Trade on OTCQB Market
- Aptose Announces Deferral of Interest Payment
- Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
- Aptose Provides Corporate Updates
- Aptose (APS) announces data from TUSCANY trial evaluating tuspetinib
- Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
APTOF and APS Related Press Releases
Go Back- Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
- Aptose Reports First Quarter 2026 Results
- Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
- Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
- Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
- Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
- Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
- Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
- Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
- Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
- Aptose Reports Third Quarter 2025 Results
- Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
- Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
- Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
- Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
- Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
- Aptose Reports Second Quarter 2025 Results
- Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
- Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
- Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML
- Aptose Upgraded to Trade on OTCQB Market
- Aptose Announces Deferral of Interest Payment
- Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
- Aptose Provides Corporate Updates
- Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
APTOF and APS Related SEC Filings
Go Back- Form 8-K Aptose Biosciences Inc. For: May 29
- Form 10-Q Aptose Biosciences Inc. For: Mar 31
- Form 8-K Aptose Biosciences Inc. For: May 13
- Form 8-K Aptose Biosciences Inc. For: Apr 30
- Form SC 13E3/A Aptose Biosciences Inc. Filed by: Aptose Biosciences Inc.
- Form 10-K Aptose Biosciences Inc. For: Dec 31
- Form 8-K Aptose Biosciences Inc. For: Mar 31
- Form 8-K Aptose Biosciences Inc. For: Mar 31
- Form RW Aptose Biosciences Inc.
- Form 8-K Aptose Biosciences Inc. For: Mar 12
- Form 8-K Aptose Biosciences Inc. For: Mar 23
- Form 8-K Aptose Biosciences Inc. For: Mar 19
- Form SC 13E3/A Aptose Biosciences Inc. Filed by: Aptose Biosciences Inc.
- Form DEFM14A Aptose Biosciences Inc.
- Form 8-K Aptose Biosciences Inc. For: Feb 23
- Form SC 13E3/A Aptose Biosciences Inc. Filed by: Aptose Biosciences Inc.
- Form PRER14A Aptose Biosciences Inc.
- Form SC 13E3/A Aptose Biosciences Inc. Filed by: Aptose Biosciences Inc.
- Form PRER14A Aptose Biosciences Inc.
- Form PRER14A Aptose Biosciences Inc.
- Form SC 13E3 Aptose Biosciences Inc. Filed by: Aptose Biosciences Inc.
- Form 8-K Aptose Biosciences Inc. For: Dec 19
